The Beginning of The End For Dementia

Dementia is a growing global health crisis, affecting millions of people worldwide. According to recent estimates, over 55 million individuals are currently living with dementia worldwide, with nearly 10 million new cases diagnosed each year. Despite extensive research, dementia diagnosis remains a challenge and many individuals find themselves grappling with the fear of cognitive decline, unsure of their future.

Early detection is crucial in managing this disease, yet providing patients with concrete answers has proven difficult. Based in Harley Street, London, we at Echelon Health, specialise in comprehensive private health assessments, which has earned us a reputation worldwide for excellence in identifying potential health risks before they become serious problems.

With a commitment to revolutionising the way dementia is approached, we are proud to launch the Gold Standard for Definitive Private Dementia Assessment. This ground-breaking assessment offers unprecedented clarity in dementia diagnosis, providing accurate insights into the risk of developing this disease.

In this article, we will explore the significance of early dementia detection and introduce Echelon Health’s ground-breaking screening pathway designed to accurately predict your risk of developing dementia.

What Is Dementia and Why Early Detection Matters

Dementia is a term used to describe a range of conditions characterised by the gradual loss of brain function, including memory, thinking and reasoning. This condition affects almost 1 million people in the UK alone, and the numbers are rising. It is currently the seventh leading cause of death and one of the major causes of disability and dependency among older people globally. Studies show that after the age of 65, the risk of developing dementia doubles every five years, making early detection and intervention more critical than ever.

Dementia symptoms can take many forms, with each type affecting the brain in different ways, which is why understanding and identifying early symptoms is crucial for effective care and management.

Different Types of Dementia

1. Alzheimer’s Disease (AD): AD is the most common cause of dementia, accounting for 65-70% of cases in the UK. Alzheimer’s is a progressive disease that begins with mild memory loss and gradually affects other cognitive functions. It is characterised by the build-up of amyloid plaques and tau protein tangles in the brain, which can disrupt the functioning of nerve cells.
2. Vascular Dementia: The second most common form, vascular dementia is caused by damage to the blood vessels that supply oxygen and nutrients to the brain. This type of dementia often follows a stroke or a series of small strokes and can lead to problems with planning, organising and making decisions.
3. Dementia with Lewy Bodies: Accounting for approximately 10-15% of cases, this type of dementia is associated with abnormal protein deposits, known as Lewy bodies, in the brain’s nerve cells. Symptoms can include fluctuations in attention and alertness, visual hallucinations and movement difficulties similar to Parkinson’s disease.
4. Frontotemporal Dementia: A rarer form, frontotemporal dementia makes up less than 3% of cases, and it is much more common in younger people than older, typically between the ages of 45 and 64. It affects the frontal and temporal lobes of the brain, which control personality, emotions and behaviour. This can lead to significant changes in behaviour and personality, as well as difficulties with language and comprehension.
5. Mixed Dementia: Some individuals have more than one type of dementia, often a combination of Alzheimer’s disease and vascular dementia. This can complicate diagnosis and treatment, making early and accurate assessment even more important.

Each type of dementia affects the brain differently, which means that the symptoms, progression and appropriate treatments can vary significantly. Therefore, distinguishing between these types is crucial for proper care and management.

What is Mild Cognitive Impairment (MCI)?

Mild Cognitive Impairment (MCI) is a condition that sits between the expected cognitive decline of normal ageing and the more serious decline of dementia. People with MCI experience noticeable problems with memory, language, thinking or judgment, but these issues are not severe enough to interfere significantly with daily life. Common symptoms of MCI include:

• Memory Problems: Misplacing items or trouble remembering recent conversations.
• Attention Difficulties: Finding it hard to concentrate, such as during a TV programme or work task.
• Disorientation: Confusion about time, date or place.
• Thinking Skills: Problems with planning or completing tasks, like managing finances or cooking.
• Communication Challenges: Difficulty finding the right words.
• Mood and Behaviour Changes: Increased irritability, anxiety or feelings of depression.

MCI can be a risk factor for developing dementia, but not everyone with MCI will go on to develop dementia. It is estimated that around 20% of people over the age of 65 have Mild Cognitive Impairment (MCI), and about 10% of these individuals go on to develop dementia each year.

Causes of Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) can result from various causes, some of which are reversible, such as vitamin deficiencies, thyroid disorders or side effects from medication. Other causes include:

• Mental health problems such as depression and anxiety
• Vascular problems, such as high blood pressure or diabetes
• Autoimmune conditions
• Infections
• Sleep disorders such as sleep apnoea
• Head injuries
• Normal aging

Early detection and intervention are critical because they offer the best chance of slowing or preventing the progression of dementia and allow for the management of reversible causes.

Risk Factors for Dementia

Understanding the risk factors for dementia is crucial for early detection and prevention. While some risk factors are beyond our control, such as age and genetics, others can be managed through lifestyle choices.

Here are the key lifestyle risk factors associated with dementia:

• Smoking: Smoking damages blood vessels and can contribute to the development of vascular dementia.
• Unhealthy Diet: Diets high in saturated fats, sugar and processed foods can increase the risk of high blood pressure and cholesterol. A balanced diet rich in fruits, vegetables and whole grains is recommended.
• Lack of Exercise: Physical inactivity is associated with an increased risk of cognitive decline. Regular physical activity helps maintain blood flow to the brain and supports overall brain health.
• Excessive Alcohol Consumption: Heavy drinking can lead to brain damage and increase the risk of various types of dementia.
• Social Isolation: Limited social interaction and engagement can increase the risk of cognitive decline. Staying socially connected and maintaining strong relationships can help support brain health.
• Sleep: Poor sleep quality, including conditions such as sleep apnea, can affect cognitive function and increase the risk of developing dementia. Adequate and restful sleep is essential for brain health.
• Hearing Loss and Visual Impairment: Untreated hearing loss and vision problems can contribute to social isolation and cognitive decline. Addressing these impairments through proper medical intervention can help reduce the risk.
• Head Injuries: A history of head injuries, especially repeated injuries, can increase the risk of developing dementia later in life. This is particularly noted in individuals with a history of traumatic brain injury (TBI).

Early diagnosis and intervention can be crucial in managing the symptoms of dementia, potentially slowing its progression and improving the quality of life. Lifestyle changes, medical treatments and supportive care can all play a role in mitigating risk and managing symptoms effectively.

Is There a Cure for Dementia?

Dementia is a complex set of conditions with various underlying causes, which makes finding a universal cure challenging. Although there is currently no cure for this disease, there are treatments available that can help manage symptoms and improve the quality of life for individuals with this disease.

The current treatment of dementia typically involves a combination of medication and non-pharmacological interventions. Medications such as cholinesterase inhibitors and memantine are widely used to manage dementia symptoms. Non-pharmacological interventions, such as cognitive therapies and lifestyle modifications, can also play a crucial role in supporting brain health and improving the quality of life for people with dementia.

Promising Advances in Alzheimer’s Disease

In recent years, significant strides have been made in the understanding, detection and treatment of Alzheimer’s disease. This surge in research has led to several ground-breaking developments that offer new hope for patients and their families. These include:

1. P-tau Blood Test for Dementia

One of the most promising advances is the development of blood tests that can specifically detect the presence of ‘tau’ proteins within the bloodstream. These tests have shown a remarkable ability to identify individuals with early Alzheimer’s disease with over 90% specificity. Although not yet widely available in the UK, these blood tests are expected to become a significant tool for the early detection and monitoring of Alzheimer’s in the near future.

2. Nuclear Medicine Scan for Amyloid

Another cutting-edge diagnostic tool is the nuclear medicine CT scan targeted against amyloid proteins. These scans are now available in specialist imaging centres and can detect amyloid deposits within the brain with high sensitivity and specificity. A negative scan can effectively rule out Alzheimer’s disease, providing a clearer diagnosis for patients exhibiting symptoms of cognitive decline.

3. Treatment for Alzheimer’s Disease

In recent years, ‘disease-modifying’ treatments for Alzheimer’s have seen remarkable progress. These include:

• Acetylcholinesterase Inhibitors: These medications, including Donepezil (Aricept), Rivastigmine (Exelon) and Galantamine (Reminyl), work by preventing the breakdown of acetylcholine in the brain, a chemical that helps nerve cells communicate. They are used to treat mild to moderate Alzheimer’s disease and have been shown to help manage symptoms in some patients with dementia with Lewy bodies, Parkinson’s disease dementia and mixed dementia.
• Glutamate Inhibitors: Memantine (Ebixa, Marixino or Valios) is used for moderate to severe Alzheimer’s disease. It works by blocking the effects of excessive glutamate, a chemical in the brain that can contribute to neurodegeneration. This medication is often used for patients who cannot tolerate acetylcholinesterase inhibitors.
• Newly Approved Treatments: One of the most exciting developments in the treatment of Alzheimer’s Disease is the recent approval of two new drugs by the US Food and Drug Administration (FDA). These are the first proven treatments to reduce amyloid in the brain, a key factor in Alzheimer’s development:Donanemab (Kisunla): Developed by Eli Lilly, this is the second medication approved by the FDA for treating patients with early symptoms of Alzheimer’s, such as cognitive impairment.Lecanemab (Leqembi): Last year, the FDA also approved Lecanemab (Leqembi), developed by Eisai in partnership with Biogen Inc., which showed similar effectiveness in slowing the progression of the disease.

While some of these treatments are currently costly and require regular administration, they offer new hope for managing and potentially altering the course of the disease.

Can I Predict My Risk of Dementia?

Recent studies have underscored the importance of early diagnosis in managing cognitive impairment and dementia. We now know that the earlier a diagnosis is made, the more effective treatment can be, potentially slowing the progression of this disease and improving quality of life. But is there a way to predict who will develop dementia?

The Gold Standard for Assessing Dementia

Our world-leading specialists at Echelon Health have developed the gold standard in predicting your risk of developing dementia. This health assessment offers unparalleled insights into your cognitive health and empowering you to take proactive steps towards a brighter future.

Echelon Health’s Dementia Screening

Our dementia assessment is at the forefront of private cognitive health assessment, offering an unmatched combination of innovative testing, expert evaluation and comprehensive care to detect the signs of dementia early on. It includes the following:

1. In-Depth Blood Tests:

The assessment process begins with a series of in-depth blood tests designed to identify risk factors associated with cognitive impairment. These tests include a full panel covering haematology, renal and liver function, diabetes markers, cholesterol and its sub-types, thyroid function, as well as levels of essential vitamins such as vitamin D, B12 and folic acid. Markers of inflammation are also evaluated to provide a complete picture of an individual’s health status.

2. Advanced 3T MRI Brain Scan:

As part of our comprehensive assessment, clients will undergo a state-of-the-art 3T MRI brain scan in incredibly detailed imaging, analysed by the lead neuroradiologist from the National Hospital for Neurology and Neurosurgery in London. The high-resolution imaging allows for the detection of subtle changes in brain structure that may indicate early signs of cognitive impairment or neurodegenerative conditions.

3. Comprehensive Neuropsychological Assessment:

Following the MRI scan, clients undergo a comprehensive neuropsychological assessment conducted by our specialist, the Head of the Marylebone Memory Clinic and a leading expert in cognitive decline, which involves a detailed evaluation lasting approximately one hour. During the assessment, we will review your medical history, discuss the results of your blood tests and MRI scan, and offer tailored advice on lifestyle modifications

Unlike standard online tests, which may not accurately detect mild cognitive impairment (MCI) in high-achieving individuals, our gold standard neuropsychological and cognitive assessment comprehensively evaluates a wide range of mental functions, such as:

• General intellect
• Reading and comprehension
• Language usage and understanding
• Attention and concentration
• Processing speed
• Learning and memory
• Reasoning and executive functions
• Visuospatial skills
• Motor speed and dexterity
• Mood and personality

4. Nuclear Medicine CT-PET Scan:

If our specialist observes any concerning signs, a nuclear medicine CT-PET scan targeting amyloid may be recommended. This advanced imaging test can identify amyloid deposits in the brain, a key characteristic of Alzheimer’s disease, providing additional diagnostic information.

5. Bespoke Support:

Following the assessment, clients receive personalised counselling on the most recent treatments for dementia, including newly approved drugs that target amyloid proteins. We also provide tailored lifestyle recommendations to optimise brain health and potentially slow the progression of cognitive decline.

This comprehensive approach ensures a thorough understanding of your cognitive health enabling the identification of subtle impairments that might otherwise go undetected. Our Health Assessment Packages, including our dementia screening, are unmatched, offering an in-depth, multi-disciplinary evaluation that provides clients with definitive answers and actionable insights.

Hope for the Future

While we do not yet have a cure for dementia, emerging treatments and advancements in early detection, such as our gold standard dementia assessment, represent a significant leap forward in the fight against dementia. This assessment is a major step towards early diagnosis and management, empowering individuals to take proactive steps to preserve their cognitive health.

At Echelon Health, we are meticulous in our assessment of your health, leaving no stone unturned to provide you with complete peace of mind.

Invest in Your Health

We understand that financial considerations can sometimes prevent people from accessing top-tier healthcare. This is why we offer flexible payment options to make our Health Assessment Packages more accessible.

To Schedule Your Appointment:

• Visit Our Website: Explore our comprehensive Health Assessment Packages.
• Contact Us: For more information or to schedule a confidential consultation with our Head of Private Clients, contact us today.

Our dedicated team is here to answer your questions, guide you through the booking process and help you take control of your health.

??Sources:

https://www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Currently%20more%20than%2055%20million,injuries%20that%20affect%20the%20brain

https://www.england.nhs.uk/mental-health/dementia/#:~:text=Dementia%20is%20a%20growing%20challenge,cancer%2C%20heart%20disease%20and%20stroke

https://www.who.int/news-room/fact-sheets/detail/dementia

https://www.alzheimers.org.uk/news/2019-09-05/protein-tangles-linked-dementia-seen-first-time-patients-brains-after-single-head?gad_source=1&gclid=Cj0KCQjwrp-3BhDgARIsAEWJ6SyqjUXk4vQ6OZfPzkjDkSD6G3YVl_oqgVimIgF-3vBv8XhqMh1WIG0aAnPLEALw_wcB&gclsrc=aw.ds

https://www.alzheimers.org.uk/about-dementia/types-dementia/dementia-with-lewy-bodies

https://www.alzheimers.org.uk/about-dementia/types-dementia/what-causes-young-onset-dementia#:~:text=Frontotemporal%20dementia%20is%20caused%20by,ages%20of%2045%20and%2065

https://alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment#:~:text=Approximately%2012%25%20to%2018%25%20of,develop%20dementia%20within%20five%20years.

https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2020.00257/full

https://www.mayoclinic.org/diseases-conditions/dementia/symptoms-causes/syc-20352013#:~:text=Physical%20activity%20and%20social%20interaction,dementia%20and%20blood%20vessel%20conditions

https://www.nhs.uk/conditions/dementia/about-dementia/cure/#:~:text=There%20is%20currently%20no%20cure,and%20dementia%20with%20Lewy%20bodies

https://www.health.harvard.edu/mind-and-mood/blood-test-shows-promise-as-simple-test-for-alzheimers-disease

https://tech.snmjournals.org/content/41/1/11

https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory

https://www.yalemedicine.org/news/lecanemab-leqembi-new-alzheimers-drug#:~:text=Sold%20under%20the%20brand%20name,intravenous%20infusion%20every%20two%20weeks

https://www.uclh.nhs.uk/our-services/our-hospitals/national-hospital-neurology-and-neurosurgery

https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early